Roche's Avastin nabs cervical cancer use in EU; Havas lays off staffers in wake of Merck OTC loss;

> Roche's ($RHHBY) Avastin won European approval as a treatment for women with advanced cervical cancer. Release

> Havas laid off more than a dozen workers after Bayer bought Merck & Co.'s ($MRK) consumer drug business and pulled Merck's OTC brand accounts from the agency. Report

> Public Citizen is asking the FDA to call a halt to diabetes drug ads that mention weight loss, despite current language emphasizing that the meds aren't diet drugs. Report

> Gilead Sciences ($GILD) filed its latest HIV therapy for approval in the U.S.; it's a combo drug comprising Emtriva (emtricitabine), and a low-dose formula of tenofovir, the active ingredient in its existing drug Viread. Report

> Using cost-effectiveness as a way to build a drug formulary cut pharmacy costs by 3% in a study of one Blue Cross program. Report

And Finally... Talk about direct-to-patient delivery: Amazon ($AMZN) Prime Air could eventually allow scripts dispensing via drone. Report

Suggested Articles

After showing Nucala could cut the rates of flares for hypereosinophilic syndrome, GSK is planning regulatory filings in 2020.

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Both IL-17A inhibitors have rolled out data showing they work in non-radiographic axial spondyloarthritis.